Investigating how proteasome dysfunction contributes to Alzheimer's disease risk and progression
Proteasome dysfunction as a driver of age-associated risk for Alzheimer's disease onset and progression
This study is looking at how problems with a part of our cells called the proteasome might contribute to Alzheimer's disease, and it aims to find ways to improve or fix this issue to help slow down memory loss and other symptoms for people with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10875733 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of proteasome dysfunction in the development and worsening of Alzheimer's disease (AD). Researchers will use both invertebrate and vertebrate models to explore how enhancing or impairing proteasome function affects AD-like symptoms. The study aims to identify mechanisms linking proteasome activity to AD progression and evaluate potential interventions that could slow or reverse cognitive decline. By examining genetic and pharmacological approaches, the research seeks to provide insights into new treatment strategies for AD.
Who could benefit from this research
Good fit: Ideal candidates for this research include older adults at risk for Alzheimer's disease or those showing early signs of cognitive decline.
Not a fit: Patients with advanced Alzheimer's disease or those with other forms of dementia unrelated to proteasome dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that slow down or even reverse the symptoms of Alzheimer's disease.
How similar studies have performed: Previous research has shown promising results in manipulating proteasome function in animal models, indicating potential for success in this area.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Pickering, Andrew Michael — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Pickering, Andrew Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.